title: Post-training infusion of glutamate into the bed nucleus of the stria terminalis enhanced inhibitory avoidance memory: an effect involving norepinephrine.
abstract: This study examined an interaction between glutamate and norepinephrine in the bed nucleus of the stria terminalis (BNST) in modulating affective memory formation. Male Wistar rats with indwelling cannulae in the BNST were trained on a one-trial step-through inhibitory avoidance task and received pre- or post-training intra-BNST infusion of glutamate, norepinephrine or their antagonists. Results of the 1-day test indicated that post-training intra-BNST infusion of DL-2-amino-5-phosphonovaleric acid (APV) impaired retention in a dose- and time-dependent manner, while infusion of glutamate had an opposite effect. Co-infusion of 0.2microg glutamate and 0.02microg norepinephrine resulted in marked retention enhancement by summating non-apparent effects of the two drugs given at a sub-enhancing dose. The amnesic effect of 5.0microg APV was ameliorated by 0.02microg norepinephrine, while the memory enhancing effect of 1.0microg glutamate was attenuated by 5.0microg propranolol. These findings suggest that training on an inhibitory avoidance task may alter glutamate neurotransmission, which by activating NMDA receptors releases norepinephrine to modulate memory formation via beta adrenoceptors in the BNST.
authors.affiliation: Department of Psychology, National Taiwan University, Taiwan, ROC.
authors.forename: Tzu-Lan
authors.initials: TL
authors.lastname: Liu
authors.forename: Der-Yow
authors.initials: DY
authors.lastname: Chen
authors.forename: K C
authors.initials: KC
authors.lastname: Liang
mesh_terms: D000161:Acoustic Stimulation; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D000704:Analysis of Variance; D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D004597:Electroshock; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage; D018698:Glutamic Acid / Q000008:administration & dosage* / Q000378:metabolism*; D008297:Male; D008568:Memory / Q000187:drug effects / Q000502:physiology*; D009043:Motor Activity / Q000187:drug effects; D009638:Norepinephrine / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011433:Propranolol / Q000008:administration & dosage; D051381:Rats; D017208:Rats, Wistar; D012686:Septal Nuclei / Q000187:drug effects / Q000502:physiology*; D014633:Valine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D000319:Adrenergic beta-Antagonists; D018691:Excitatory Amino Acid Antagonists; D018698:Glutamic Acid; C056639:2-amino-5-phosphopentanoic acid; D011433:Propranolol; D014633:Valine; D009638:Norepinephrine